H. Lundbeck Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Charl van Zyl

Chief Executive Officer (CEO)

DKK 39.6m

Compensación total

Porcentaje del salario del CEO	6.8%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Charl van Zyl en comparación con los beneficios de H. Lundbeck?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

Compensación vs. Mercado: La compensación total de Charl($USD5.70M) está por encima de la media de empresas de tamaño similar en el mercado Austrian ($USD2.09M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Charl con los resultados de la empresa.

CEO

Charl van Zyl (57 yo)

less than a year

Permanencia

DKK 39,600,000

Compensación

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Charl van Zyl	President & CEO	less than a year	DKK 39.60m	sin datos
Joerg Hornstein	CFO & Executive VP of Corporate Functions	2.1yrs	DKK 10.90m	0.0023% DKK 130.1k
Lars Bang	Executive Vice President of Product Development & Supply	5.7yrs	DKK 10.10m	0.038% DKK 2.2m
Per Luthman	Executive Vice President of Research & Development	5.7yrs	DKK 11.30m	0.014% DKK 801.4k
Tarek Samad	Senior VP & Head of Research	3.3yrs	sin datos	sin datos
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	sin datos	sin datos
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	sin datos	sin datos
Dianne Holto	Executive Vice President of People & Culture	less than a year	sin datos	sin datos
Ole Chrintz	Senior Vice President of International Markets	no data	sin datos	sin datos
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.7yrs	sin datos	sin datos
Bjorn Mogensen	Senior Vice President of Group Finance	2.1yrs	sin datos	sin datos
Jose Molinuevo	VP & Head of Experimental Medicine	no data	sin datos	sin datos

2.1yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LUNA se considera experimentado (2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lars Rasmussen	Independent Chairman	11.7yrs	DKK 1.70m	0.010% DKK 577.9k
Lene Skole-Sorensen	Deputy Chairman	9.7yrs	DKK 1.20m	0.0062% DKK 354.3k
Jeffrey Berkowitz	Independent Director	6.5yrs	DKK 1.20m	sin datos
Lars Holmqvist	Director	9.7yrs	DKK 600.00k	0.0076% DKK 433.4k
Jakob Riis	Director	1.5yrs	DKK 450.00k	0.0055% DKK 313.0k
Ilse Wenzel	Independent Director	3.5yrs	DKK 70.00k	sin datos
Santiago Arroyo	Independent Director	3.5yrs	DKK 1.00m	sin datos
Camilla Andersson	Employee Representative Director	2.5yrs	DKK 400.00k	0.00010% DKK 5.7k
Dorte Clausen	Employee Representative Director	2.5yrs	DKK 400.00k	0.00011% DKK 6.3k
Hossein Armandi	Employee Representative Director	2.5yrs	DKK 400.00k	sin datos
Lasse Skibsbye	Employee Representative Director	2.5yrs	DKK 400.00k	sin datos

3.5yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de LUNA se considera experimentada (3.3 años de antigüedad promedio).

H. Lundbeck Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

Less than half of directors are independent

Recent updates

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

Less than half of directors are independent

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad